文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

基于材料的传染病疫苗。

Materials-based vaccines for infectious diseases.

机构信息

Department of Materials Science and Engineering, University of Illinois at Urbana-Champaign, Urbana, Illinois, USA.

Cancer Center at Illinois (CCIL), Urbana, Illinois, USA.

出版信息

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022 Sep;14(5):e1824. doi: 10.1002/wnan.1824. Epub 2022 Jun 16.


DOI:10.1002/wnan.1824
PMID:35708013
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9541041/
Abstract

Infectious diseases that result from pathogen infection are among the leading causes of human death, with pathogens such as human immunodeficiency virus, malaria, influenza, and ongoing SARS-COV-2 viruses constantly threatening the global population. While the mechanisms behind various infectious diseases are not entirely clear and thus retard the development of effective therapeutics, vaccines have served as a universal approach to containing infectious diseases. However, conventional vaccines that solely consist of antigens or simply mix antigens and adjuvants have failed to control various highly infective or deadly pathogens. Biomaterials-based vaccines have provided a promising solution due to their ability to synergize the function of antigens and adjuvants, troubleshoot delivery issues, home and manipulate immune cells in situ. In this review, we will summarize different types of materials-based vaccines for generating cellular and humoral responses against pathogens and discuss the design criteria for amplifying the efficacy of materials-based vaccines against infectious diseases. This article is categorized under: Therapeutic Approaches and Drug Discovery > Nanomedicine for Infectious Disease.

摘要

由病原体感染引起的传染病是人类死亡的主要原因之一,人类免疫缺陷病毒、疟疾、流感和持续存在的 SARS-COV-2 病毒等病原体不断威胁着全球人口。虽然各种传染病的发病机制尚不完全清楚,从而阻碍了有效治疗方法的发展,但疫苗已成为控制传染病的通用方法。然而,仅由抗原组成或简单混合抗原和佐剂的传统疫苗未能控制各种高度传染性或致命性的病原体。基于生物材料的疫苗由于能够协同抗原和佐剂的功能、解决传递问题、在原位调节和操纵免疫细胞而提供了有希望的解决方案。在这篇综述中,我们将总结不同类型的基于材料的疫苗,用于针对病原体产生细胞和体液反应,并讨论放大基于材料的疫苗对抗传染病的功效的设计标准。本文属于以下分类:治疗方法和药物发现 > 用于传染病的纳米医学。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbe8/9541041/5852d5bd6960/WNAN-14-e1824-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbe8/9541041/57214893fbe7/WNAN-14-e1824-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbe8/9541041/bc19a10d7752/WNAN-14-e1824-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbe8/9541041/cd22569f5cbb/WNAN-14-e1824-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbe8/9541041/ca0611807efd/WNAN-14-e1824-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbe8/9541041/5852d5bd6960/WNAN-14-e1824-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbe8/9541041/57214893fbe7/WNAN-14-e1824-g006.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbe8/9541041/bc19a10d7752/WNAN-14-e1824-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbe8/9541041/cd22569f5cbb/WNAN-14-e1824-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbe8/9541041/ca0611807efd/WNAN-14-e1824-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/fbe8/9541041/5852d5bd6960/WNAN-14-e1824-g005.jpg

相似文献

[1]
Materials-based vaccines for infectious diseases.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2022-9

[2]
Advancements in protein nanoparticle vaccine platforms to combat infectious disease.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2021-5

[3]
SARS-CoV-2 will constantly sweep its tracks: a vaccine containing CpG motifs in 'lasso' for the multi-faced virus.

Inflamm Res. 2020-7-12

[4]
Emerging skin-targeted drug delivery strategies to engineer immunity: A focus on infectious diseases.

Expert Opin Drug Deliv. 2021-2

[5]
Nanovaccines to combat virus-related diseases.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2023-3

[6]
Adenovirus Encoded Adjuvant (AdEnA) anti-CTLA-4, a novel strategy to improve Adenovirus based vaccines against infectious diseases and cancer.

Front Immunol. 2023

[7]
Immunobiology of Carbohydrates: Implications for Novel Vaccine and Adjuvant Design Against Infectious Diseases.

Front Cell Infect Microbiol. 2021

[8]
Lipid-based vaccine nanoparticles for induction of humoral immune responses against HIV-1 and SARS-CoV-2.

J Control Release. 2021-2-10

[9]
Recent advances on smart glycoconjugate vaccines in infections and cancer.

FEBS J. 2022-7

[10]
Immunomodulators as adjuvants for vaccines and antimicrobial therapy.

Ann N Y Acad Sci. 2010-10-4

引用本文的文献

[1]
A Novel Triptolide Nano-Liposome with Mitochondrial Targeting for Treatment of Hepatocellular Carcinoma.

Int J Nanomedicine. 2024-12-3

[2]
Engineered protein subunit COVID19 vaccine is as immunogenic as nanoparticles in mouse and hamster models.

Sci Rep. 2024-10-26

[3]
Current Challenges of Vaccination in Fish Health Management.

Animals (Basel). 2024-9-16

[4]
Directly visualizing individual polyorganophosphazenes and their single-chain complexes with proteins.

Commun Mater. 2024

[5]
Metabolic tagging of extracellular vesicles and development of enhanced extracellular vesicle based cancer vaccines.

Nat Commun. 2023-12-5

[6]
Cryo-EM and AFM visualize linear polyorganophosphazene: individual chains and single-chain assemblies with proteins.

Res Sq. 2023-10-31

本文引用的文献

[1]
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA.1 and BA.2 by convalescent and vaccine serum and monoclonal antibodies.

EBioMedicine. 2022-8

[2]
Scientists hail historic malaria vaccine approval - but point to challenges ahead.

Nature. 2021-10-8

[3]
Designing spatial and temporal control of vaccine responses.

Nat Rev Mater. 2022

[4]
mRNA vaccines for infectious diseases: principles, delivery and clinical translation.

Nat Rev Drug Discov. 2021-11

[5]
Biomaterial vaccines capturing pathogen-associated molecular patterns protect against bacterial infections and septic shock.

Nat Biomed Eng. 2022-1

[6]
Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization.

Nature. 2021-8

[7]
A liposome-displayed hemagglutinin vaccine platform protects mice and ferrets from heterologous influenza virus challenge.

Proc Natl Acad Sci U S A. 2021-6-1

[8]
BNT162b2 vaccine induces neutralizing antibodies and poly-specific T cells in humans.

Nature. 2021-7

[9]
Extracellular vesicles as antigen carriers for novel vaccination avenues.

Adv Drug Deliv Rev. 2021-6

[10]
Quadrivalent influenza nanoparticle vaccines induce broad protection.

Nature. 2021-4

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索